** Shares of cell-based therapy company THMO.O rise 15% to
$3.60
** Co notifies U.S. FDA of intent to distribute its
point-of-care coronavirus kit intended for professional use,
which delivers results in less than 10 minutes urn:newsml:reuters.com:*:nPn8B8Hjfa
** THMO is currently completing validations in accordance
with Policy for Diagnostic Test for Coronavirus Disease-2019,
and will notify FDA prior to product launch
** Test not only pre-screens for COVID-19 infections, but
also identifies individuals who have encountered the virus and
have developed protective immunity - THMO
** Shares more than doubled on March 24 after co said it was
working with ImmuneCyte to develop, register, import and seek
U.S. FDA approval for a COVID-19 detection test urn:newsml:reuters.com:*:nL4N2BG46U
** Including session's gain, shares fell ~18% YTD
(Reporting By Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))